SecBot SecBot
8-K ·Filed Sep 21, 2026

IBAC

IB Acquisition Corp.
BEARISH
Impact 6/10
Horizonweeks Processed1mo ago SEC0001493152-26-043585
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▼ Bearish

Monitor the closing of the business combination with GNQ Insilico and the subsequent effectiveness of the registration statements. The equity facility allows IBAC to sell shares at a discount, which could pressure the stock price if drawn upon aggressively. Watch for stockholder vote on the authorized share increase and reverse split.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
IBAC ▼ -5.57% at T+20d
SHORT call ✓ call won +5.57% · α vs SPY +5.01% · entry $11.50 → $10.86
Next anchor: T+60d in 7w
Latest observation: T+23 +7.44% FF3 residual α
Entry = T+0 close
Sep 21, 2026
via day close
T+1d
-0.87%
call +0.87% · α +0.15%
$11.40
settled 5w ago
T+5d
-3.48%
call +3.48% · α +2.29%
$11.10
settled 29d ago
T+20d
-5.57%
call +5.57% · α +5.01%
$10.86
settled 8d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

IB Acquisition Corp. (IBAC) entered into a Securities Purchase Agreement with investors including ATW Quantum Bio LLC for the sale of up to $106.47 million in senior secured convertible notes, with an initial closing of up to $16.47 million at ~85% of par, and a separate Equity Purchase Facility Agreement with SZOP Opportunities I LLC for up to $50 million in common stock at a discount to market prices. These financings are contingent on the closing of IBAC's business combination with GNQ Insilico Inc. and provide working capital but introduce significant potential dilution and debt-like obligations.

Key Facts

  • IBAC entered into a Securities Purchase Agreement for up to $106,470,588 in senior secured convertible notes, with an initial tranche of up to $16,470,588 at ~85% of par ($850 per $1,000 principal).
  • IBAC entered into an Equity Purchase Facility Agreement with SZOP Opportunities I LLC for up to $50 million in common stock, sold at 97-98% of market price.
  • Both financings are contingent on the closing of the business combination with GNQ Insilico Inc., which is structured as an arrangement under Canadian law.
  • The convertible notes are senior secured, ranking ahead of all other indebtedness, and secured by substantially all assets of the company and its subsidiaries.
  • The equity facility allows IBAC to sell shares at a discount to market, with pricing periods ranging from accelerated (same-day) to regular (3-day) and extended/overtime periods.
  • Proceeds from the initial note closing will include $5 million deposited as restricted cash, with the remainder for working capital and transaction expenses.
  • The company must obtain stockholder approval to increase authorized shares from 100 million to 1 billion and approve a reverse stock split up to 250:1.
  • The business combination involves IBAC converting from Nevada to Delaware corporation, with existing target shares and notes exchanged for common stock and new convertible notes.
  • The equity facility includes a 4.99% beneficial ownership limitation for the investor and is subject to an exchange cap of 19.99% of outstanding shares unless stockholder approval is obtained.
  • The company is obligated to file a registration statement for resale of the shares issued under both facilities.

Financial Impact

Up to $106.47 million in senior secured convertible notes (initial $16.47M at ~85% of par) plus up to $50 million equity facility at 97-98% of market price; significant potential dilution from conversion of notes and equity draws.

dilutiondebtcashworking capital

Risk Factors

  • Massive potential dilution from conversion of up to $106.47M in convertible notes and up to $50M in equity facility shares.
  • Senior secured note structure subordinates existing and future creditors, increasing financial risk.
  • Equity facility pricing at a discount to market (97-98%) creates a structural downward pressure on the stock price.
  • Business combination may not close, rendering the financings void and leaving IBAC as a SPAC without a target.
  • Stockholder approval required for share increase and reverse split may not be obtained, limiting the company's ability to issue shares.
  • The company's common stock may face delisting if it fails to maintain Nasdaq listing standards.

Investment Themes

Traditional Finance

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-043585
Exhibit: ex10-1.htm0001493152-26-043585
5 reports for IBAC
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IBAC — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$10.86 $10.86· 0.00%▼ −0.09%$10.86 (−0.00%)
Oct 6, 2026
20d ago
8-K
BEARISH ★ 6/10
$10.88 $10.86▲ +0.18%▼ −0.80%$10.86 (+0.18%)
Sep 23, 2026
4w ago
425
BEARISH ★ 6/10
$11.30 $10.91▲ +3.45%▲ +3.04%$10.86 (+3.89%)
Sep 21, 2026
5w ago
425
NEUTRAL ★ 4/10
$11.50 $11.10▼ −3.48%▼ −2.29%$10.86 (−5.57%)
Sep 21, 2026
5w ago
8-K
BEARISH ★ 6/10
$11.50 $11.10▲ +3.48%▲ +2.29%$10.86 (+5.57%)
Showing 5 of 5

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 21, 2026